Showing results (101-110 of 176) with videos related to
Sort By:
Pageof 18
Clinical Lung Cancer|December 25, 2024
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System DiseaseChang Lu, Hong-Hong Yan, Chan-Yuan Zhang, et al.Clinical Lung Cancer|October 12, 2015
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLCYuan-Yuan Lei, Jin-Ji Yang, Xu-Chao Zhang, et al.Translational Lung Cancer Research|November 14, 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancerJiao Yang, Jun-Wei Su, Hong-Rui Li, et al.British Journal of Cancer|April 4, 2024
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISIONTerufumi Kato, James Chih-Hsin Yang, Myung-Ju Ahn, et al.Cancers|January 8, 2023
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLCGuang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancerQing Zhou, Xu-Chao Zhang, Zhi-Hong Chen, et al.European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatmentsMei-Mei Zheng, Hai-Yan Tu, Jin-Ji Yang, et al.Experimental Hematology & Oncology|November 11, 2021
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsLun-Xi Peng, Guang-Ling Jie, An-Na Li, et al.Journal of Genetics and Genomics = Yi Chuan Xue Bao|November 12, 2015
Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome SequencingLu-Lu Yang, Xu-Chao Zhang, Shao-Kun Chuai, et al.Cancer Immunology, Immunotherapy : CII|December 8, 2017
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screeningXu-Chao Zhang, Xu Cao, Chun Sun, et al.Pageof 18